Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

[1]  Sarah H. Johnson,et al.  Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer , 2015, Oncotarget.

[2]  R. Shah,et al.  Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. , 2015, Human pathology.

[3]  Travis M. Drucker,et al.  BIMA V3: an aligner customized for mate pair library sequencing , 2014, Bioinform..

[4]  J. Hicks,et al.  PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy , 2014, Modern Pathology.

[5]  R. Gibbs,et al.  Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. , 2013, Gastroenterology.

[6]  Sarah H. Johnson,et al.  Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. , 2013, Cancer research.

[7]  A. Evans,et al.  PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade , 2013, Modern Pathology.

[8]  J. Hicks,et al.  Cytoplasmic PTEN Protein Loss Distinguishes Intraductal Carcinoma of the Prostate from High Grade Prostatic Intraepithelial Neoplasia , 2012, Modern Pathology.

[9]  Sarah H. Johnson,et al.  Mate Pair Sequencing of Whole-Genome-Amplified DNA Following Laser Capture Microdissection of Prostate Cancer , 2012, DNA research : an international journal for rapid publication of reports on genes and genomes.

[10]  David I. Smith,et al.  Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. , 2012, Blood.

[11]  J. Epstein,et al.  Do Adenocarcinomas of the Prostate With Gleason Score (GS)⩽6 Have the Potential to Metastasize to Lymph Nodes? , 2012 .

[12]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[13]  C. Cooper,et al.  Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer , 2012, Modern Pathology.

[14]  Jianfeng Xu,et al.  PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients , 2011, Clinical Cancer Research.

[15]  J. Squire,et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer , 2011, BJU international.

[16]  M. Shen,et al.  Molecular genetics of prostate cancer: new prospects for old challenges. , 2010, Genes & development.

[17]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[18]  Pier Paolo Pandolfi,et al.  Subtle variations in Pten dose determine cancer susceptibility , 2010, Nature Genetics.

[19]  W. Gerald,et al.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer , 2010, British Journal of Cancer.

[20]  R. Shah,et al.  Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression , 2009, Modern Pathology.

[21]  F. Saad,et al.  PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancer , 2009, The Journal of pathology.

[22]  J. Squire.  TMPRSS2-ERG and PTEN loss in prostate cancer , 2009, Nature Genetics.

[23]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[24]  F. Jirik,et al.  The Pace of Prostatic Intraepithelial Neoplasia Development Is Determined by the Timing of Pten Tumor Suppressor Gene Excision , 2008, PloS one.

[25]  O. Ludkovski,et al.  Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.

[26]  K. Nielsen,et al.  Is PTEN loss associated with clinical outcome measures in human prostate cancer? , 2008, British Journal of Cancer.

[27]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[28]  Paulo A. S. Nuin,et al.  Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer genetics and cytogenetics.

[29]  Mitsutoshi Nakamura,et al.  Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. , 2002, The American journal of pathology.

[30]  J. Cheville,et al.  Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer , 2002, The American journal of surgical pathology.

[31]  M. Ittmann,et al.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[33]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[34]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[35]  O. Cussenot,et al.  PTEN/MMAC1/TEP1 involvement in primary prostate cancers , 1998, Oncogene.

[36]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Feilotter,et al.  Analysis of PTEN and the 10q23 region in primary prostate carcinomas , 1998, Oncogene.

[38]  M. Ittmann,et al.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[40]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.